DaVita (DVA)
(Delayed Data from NYSE)
$139.68 USD
+1.96 (1.42%)
Updated Jul 17, 2024 04:00 PM ET
After-Market: $139.70 +0.02 (0.01%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$139.68 USD
+1.96 (1.42%)
Updated Jul 17, 2024 04:00 PM ET
After-Market: $139.70 +0.02 (0.01%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth B Momentum A VGM
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
Medtronic's (MDT) Newest Evolut TAVR System Gets FDA Approval
by Zacks Equity Research
Medtronic (MDT) announces the FDA approval of the newest-generation Evolut TAVR system for the treatment of symptomatic severe aortic stenosis.
McKesson (MCK) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
Chemed (CHE) Up 2.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GE HealthCare's (GEHC) PVA to Aid in Capturing Prostate Volume
by Zacks Equity Research
GE HealthCare (GEHC) announces the launch of Prostate Volume Assist AI-enabled urology software feature, which is likely to boost prostate imaging, capture prostate volume and increase workflow.
3 Reasons to Retain Inogen (INGN) Stock in Your Portfolio
by Zacks Equity Research
Expanding product portfolio and high prospects for POC raise optimism for Inogen (INGN) stock.
Here's Why You Should Add Lantheus (LNTH) to Your Portfolio
by Zacks Equity Research
Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.
Boston Scientific (BSX) and Scivita Medical Expand Partnership
by Zacks Equity Research
Boston Scientific (BSX) and Scivita Medical announce an expanded strategic cooperation arrangement.
Here's Why Investors Should Retain Thermo Fisher (TMO) Stock
by Zacks Equity Research
Strength in end markets and strategic collaborations bode well for Thermo Fisher (TMO).
Accuray's (ARAY) CyberKnife Improves Prostate Cancer Treatment
by Zacks Equity Research
Accuray (ARAY) announces the latest data that supports the use of its CyberKnife System in the treatment of recurrent prostate cancer with stereotactic body radiation therapy.
DexCom (DXCM) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about DexCom's (DXCM) strong product portfolio.
Stryker's (SYK) Latest Launch to Streamline Procedural Workflows
by Zacks Equity Research
Stryker's (SYK) latest addition to its Gamma legacy is expected to streamline workflows and enhance usability.
Myriad Genetics (MYGN) Wins Foundational Patent for MRD Assay
by Zacks Equity Research
Myriad Genetics' (MYGN) new patent grant is likely to bolster the ability to deliver a tumor-informed, high-definition MRD assay to the market.
Reasons to Add Cencora (COR) Stock in Your Portfolio Now
by Zacks Equity Research
Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Masimo (MASI) Plans Consumer Business Spin-Off to Drive Growth
by Zacks Equity Research
Masimo (MASI) is evaluating a proposed separation of its consumer audio and consumer health product business in a bid to improve the profitability of the healthcare business.
Three Reasons to Retain Avantor (AVTR) Stock in Your Portfolio
by Zacks Equity Research
Avantor's (AVTR) strong product portfolio raises optimism about the stock.
Veeva Systems' (VEEV) Vault EDC Witnesses Increasing Adoption
by Zacks Equity Research
Veeva Systems' (VEEV) Vault EDC is likely to enable companies to build a modern clinical data foundation.
Reasons to Add Veeva Systems (VEEV) to Your Portfolio Now
by Zacks Equity Research
Veeva's strong product demand and strategic deals raise optimism about the stock.
GE HealthCare (GEHC) to Sell IONIC's FDA-Cleared nCommand Lite
by Zacks Equity Research
GE HealthCare (GEHC) announces the FDA approval of IONIC Health's nCommand Lite technology, which it will distribute for multi-vendor, multi-modality remote operations purposes exclusively.
Reasons to Retain Intuitive Surgical (ISRG) in Your Portfolio
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to raise optimism among investors, owing to its strength in robotics.
Charles River (CRL) Extends Gene Therapy Deal With NUS Medicine
by Zacks Equity Research
Charles River (CRL) announces the extension of the gene therapy manufacturing alliance with NUS Medicine.
Here's Why You Should Buy Align Technology (ALGN) Stock Now
by Zacks Equity Research
Investors remain optimistic about Align Technology (ALGN), backed by Invisalign's strong potential and impressive collaborations.
Are Investors Undervaluing DaVita (DVA) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Tandem Diabetes (TNDM) Gains From Innovation Amid Competition
by Zacks Equity Research
Tandem Diabetes (TNDM), in 2024, intends to advance its AID algorithm and expand its indications to include people living with Type 2 diabetes.
Stryker (SYK) Acquires SERF SAS to Aid Its Orthopedic Segment
by Zacks Equity Research
Stryker (SYK) completes its acquisition of SERF SAS, a France-based joint replacement company. With this acquisition, Stryker aims to boost its orthopedic division in the European region.
Bruker Corporation (BRKR) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Bruker Corporation (BRKR) outperforms the industry due to its strengthening portfolio and robust quarterly results.